Gastrointestinal Therapeutics in Major Developed Markets to 2019 | Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report Available by Researcmoz
Albany, NewYork (PRWEB) January 16, 2014 -- GBI Research, the leading business intelligence provider, has released its latest research, ‘Gastrointestinal Therapeutics (Irritable Bowel Syndrome, Ulcerative Colitis and Crohn’s Disease) in Major Developed Markets’, which provides insights into three gastrointestinal therapeutic indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada.
Click Here Read The Complete Report : http://www.researchmoz.us/gastrointestinal-therapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-to-counter-declines-from-patent-expiries-report.html
The report provides an in-depth analysis of three gastrointestinal therapeutics markets, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research’s team of industry experts. In 2012, the value of the gastrointestinal therapeutics market in major developed countries amounted to an estimated $6.8 billion. This total is forecast to decline at a Compound Annual Growth Rate (CAGR) of 0.3% between 2012 and 2019. The value of the IBS market amounted to an estimated $727m, and is forecast to increase at a CAGR of 14.4% between 2012 and 2019. The value of the UC market amounted to an estimated $2.2 billion in 2012, and is expected to increase at a CAGR of 6% during the forecast period. The value of the CD market amounted to an estimated $3.8 billion, which is expected to decline at a CAGR of 7.5% between 2012 and 2019.
Browse All GBI Market Research Report at http://www.researchmoz.us/publisher/gbi-research-2.html
Scope
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals for the IBS, UC and CD indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada.
The report includes:
Disease overview and treatment usage patterns
Market size and forecast for IBS, UC and CD in major developed markets from 2012 to 2019
Major marketed products for the indication types covered
In-depth pipeline analysis for IBS, UC and CD
Key drivers and restraints that have had and are expected to have a major impact upon the market
Key licensing and co-development agreements in the gastrointestinal therapeutics market
All Latest Market Research Report at http://www.researchmoz.us/latest-report.html
Reasons to Buy
This report will enhance your decision-making capability by enabling you to:
Align your product portfolio to the markets with high growth potential
Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments that are poised for strong growth
Devise a more effectively tailored country-specific strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market
Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Related Report
Ophthalmology Therapeutics Markets to 2019
GBI Research(http://www.researchmoz.us/ophthalmology-therapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-to-trigger-shift-in-treatment-paradigm-to-combination-therapies-report.html) has released its pharma research, "Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies", which provides insights into two therapeutic indications in ophthalmology in Top Eight Markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications.
Prostate Cancer Therapeutics Market to 2019
GBI Research(http://www.researchmoz.us/prostate-cancer-therapeutics-market-to-2019-rising-prevalence-and-strong-uptake-of-recent-approvals-to-drive-robust-growth-to-2019-report.html) has released the pharmaceutical report - “Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019”. The recent approval of a number of highly effective drugs, including Zytiga and Xtandi, has provided late-stage patients with a number of options and increased survival times by a number of months. These recent approvals are anticipated to generate strong revenues during the forecast following increasing uptake by physicians as the treatment algorithm shifts towards their first-line usage over Taxotere. Additionally, a very large late-stage pipeline is anticipated to produce a number of new market entrants which are superior to existing products. Overall, this is anticipated to drive rapid market growth from $4.1 billion in 2012 to $8.0 billion by 2019 at a CAGR of 10.1%.
About Us
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis.We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports.We provide our services to all sizes of organizations and across all industry verticals and markets.Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email: sales(at)researchmoz(dot)us
http://www.researchmoz.us/
Blog: http://industryresearchnews.blogspot.com
Michelle Thoras, ResearchMoz, http://www.researchmoz.us/, +1-518-618-1030, [email protected]
Share this article